https://www.benzinga.com/24/11/42073596/analyst-sees-competitive-concerns-for-silence-therapeutics-zerlasiran
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
silence therapeuticszerlasirancompetitiveconcernsanalyst